WO1999021835A1 - DERIVES DE QUINOLINE UTILISES COMME INHIBITEURS DE H+ATPase ET COMME INHIBITEURS DE RESORPTION OSSEUSE - Google Patents

DERIVES DE QUINOLINE UTILISES COMME INHIBITEURS DE H+ATPase ET COMME INHIBITEURS DE RESORPTION OSSEUSE Download PDF

Info

Publication number
WO1999021835A1
WO1999021835A1 PCT/JP1998/004841 JP9804841W WO9921835A1 WO 1999021835 A1 WO1999021835 A1 WO 1999021835A1 JP 9804841 W JP9804841 W JP 9804841W WO 9921835 A1 WO9921835 A1 WO 9921835A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
substituted
group
compound
amino
Prior art date
Application number
PCT/JP1998/004841
Other languages
English (en)
Inventor
Teruo Oku
Shigeki Satoh
Takayuki Inoue
Yasuharu Urano
Tatsuya Zenkoh
Noriko Yoshida
Original Assignee
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co., Ltd. filed Critical Fujisawa Pharmaceutical Co., Ltd.
Priority to JP52372599A priority Critical patent/JP2002510334A/ja
Publication of WO1999021835A1 publication Critical patent/WO1999021835A1/fr

Links

Classifications

    • G—PHYSICS
    • G07—CHECKING-DEVICES
    • G07F—COIN-FREED OR LIKE APPARATUS
    • G07F11/00—Coin-freed apparatus for dispensing, or the like, discrete articles
    • G07F11/02—Coin-freed apparatus for dispensing, or the like, discrete articles from non-movable magazines
    • G07F11/04—Coin-freed apparatus for dispensing, or the like, discrete articles from non-movable magazines in which magazines the articles are stored one vertically above the other
    • G07F11/14—Coin-freed apparatus for dispensing, or the like, discrete articles from non-movable magazines in which magazines the articles are stored one vertically above the other with means for raising the stack of articles to permit delivery of the topmost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G07—CHECKING-DEVICES
    • G07F—COIN-FREED OR LIKE APPARATUS
    • G07F11/00—Coin-freed apparatus for dispensing, or the like, discrete articles
    • G07F11/62—Coin-freed apparatus for dispensing, or the like, discrete articles in which the articles are stored in compartments in fixed receptacles

Definitions

  • lower in cyclo (lower) alkyl moiety in the various definitions is intended to mean a group having 3 to 6 carbon atoms.
  • Suitable reactive derivative at the carboxy group of the compound [III] may include an acid halide, an acid anhydride, an activated amide, an activated ester, and the like.
  • Suitable examples of the reactive derivatives may be an acid chloride; an acid azide; a mixed acid anhydride with an acid such as dialkylphosphoric acid, sulfuric acid, aliphatic carboxylic acid or aromatic carboxylic acid; a symmetrical acid anhydride; an activated amide with imidazole; or an activated ester [e.g. p-nitrophenyl ester, etc.].
  • These reactive derivatives can optionally be selected from them according to the kind of the compound [III] to be used.
  • Example 11 The following compounds were obtained according to a similar manner to that of Example 10.
  • Example 12 (1) 3-Chloro-8-nitro-4- (3-phenylureido) quinoline was obtained from 4-amino-3-chloro-8-nitroquinoline and aniline according to a similar manner to that of Example 9- (3) .
  • Example 14 (1) 3-Methyl-8-nitro-4-ureidoquinoline was obtained from 4-amino-3-methyl-8-nitroquinoline and 7N solution of ammonia in methanol according to a similar manner to that of Example 5-(3) .
  • mp 212.5-214°C NMR (DMSO-dg, ⁇ ) : 2.38 (3H, s) , 6.23 (2H, s) , 7.71
  • Example 15 4- (3-Ethylureido) -3-methyl-8-nitroquinoline was obtained from 4-amino-3-methyl-8-nitroquinoline and 2M solution of ethylamine in tetrahydrofuran according to a similar manner to that of Example 5- (3).
  • Example 17 (1) 3-Methyl-8-nitro-4- (3-propylureido) quinoline was obtained from 4-amino-3-methyl-8-nitroquinoline and n-propylamine according to a similar manner to that of Example 3- (4) . p : 186-190°C
  • Example 19 8-Amino-3-methyl-4- (4-toluenesulfonamido) quinoline was obtained from 3-methyl-8-nitro-4- (4-toluenesulfonamido) - quinoline according to a similar manner to that of Example 8-(2) .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Vending Machines For Individual Products (AREA)
  • Control Of Vending Devices And Auxiliary Devices For Vending Devices (AREA)

Abstract

Cette invention concerne un composé correspondant à la formule (I) où R1 représente alkyle inférieur, aryle, un groupe hétérocyclique, etc., tandis que R2 représente hydrogène, alkyle inférieur, etc. R3 représente hydrogène ou alkyle inférieur, R4 représente hydrogène, halogène, alkyle inférieur, etc., tandis que R5 et R6 représentent chacun hydrogène, etc. R7 représente un groupe hétérocyclique ou aryle, ces éléments pouvant chacun être substitués par un ou plusieurs substituants. X représente O ou S, tandis que Y représente -NHCO-, etc. Cette invention concerne également les sels de ce composé acceptables sur le plan pharmaceutique, des procédés de préparation de ces composés, une composition pharmaceutique contenant ces composés, ainsi qu'un procédé de prévention et/ou de traitement de maladies osseuses qui sont dues à un métabolisme osseux anormal chez les êtres humains comme chez les animaux.
PCT/JP1998/004841 1997-09-03 1998-10-26 DERIVES DE QUINOLINE UTILISES COMME INHIBITEURS DE H+ATPase ET COMME INHIBITEURS DE RESORPTION OSSEUSE WO1999021835A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP52372599A JP2002510334A (ja) 1997-09-03 1998-10-26 Ｈ▲上＋▼−ａｔｐアーゼ阻害剤および骨吸収阻害剤としてのキノリン誘導体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP0031A AUPP003197A0 (en) 1997-09-03 1997-09-03 New heterocyclic compounds
AUPP0031 1997-10-27

Publications (1)

Publication Number Publication Date
WO1999021835A1 true WO1999021835A1 (fr) 1999-05-06

Family

ID=3804307

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1998/004841 WO1999021835A1 (fr) 1997-09-03 1998-10-26 DERIVES DE QUINOLINE UTILISES COMME INHIBITEURS DE H+ATPase ET COMME INHIBITEURS DE RESORPTION OSSEUSE

Country Status (4)

Country Link
JP (1) JP2002510334A (fr)
AU (1) AUPP003197A0 (fr)
CA (1) CA2342804C (fr)
WO (1) WO1999021835A1 (fr)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034269A1 (fr) * 1998-12-09 2000-06-15 American Home Products Corporation Inhibiteurs de thio-uree des virus de l'herpes
WO2001017562A1 (fr) * 1999-09-02 2001-03-15 Yamanouchi Pharmaceutical Co., Ltd. Agents promoteurs de l'osteogenese
US6262082B1 (en) 1998-12-09 2001-07-17 BLOOM Jonathan Diaminopyridine-containing thiourea inhibitors of herpes viruses
WO2002085857A2 (fr) * 2001-04-20 2002-10-31 Bayer Corporation Inhibition de la kinase raf a l'aide d'urees de quinolyl, d'isoquinolyl ou de pyridyl
WO2004026836A2 (fr) * 2002-09-17 2004-04-01 Actelion Pharmaceuticals Ltd Derives de 1-pyridin-4-yl-uree
US6815451B2 (en) 2001-03-27 2004-11-09 Actelion Pharmaceuticals Ltd. 1,2,3,4-Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists
US7241758B2 (en) 1999-11-16 2007-07-10 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
US7375227B2 (en) 2001-12-04 2008-05-20 Actelion Pharmaceuticals Ltd. Quinoline derivatives
US7381744B1 (en) * 1999-03-05 2008-06-03 The United States Of America As Represented By The Department Of Health And Human Services Method of treating osteoporosis comprising vacuolar-type (H+)-ATPase-inhibiting compounds
US7750161B2 (en) 2003-09-26 2010-07-06 Daniel Bur Pyridine derivatives
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
US7897623B2 (en) 1999-01-13 2011-03-01 Bayer Healthcare Llc ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
US8067601B2 (en) 2004-10-12 2011-11-29 Actelion Pharmaceticals Ltd. 1-[2-(4-benzyl-4-hydroxy-piperidin-1 -yl )-ethyl]-3-(2-methyl-quinolin- 4-yl)- urea as crystalline sulfate salt
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20120172376A1 (en) * 2010-12-30 2012-07-05 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US8637553B2 (en) 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US8796250B2 (en) 2003-05-20 2014-08-05 Bayer Healthcare Llc Diaryl ureas for diseases mediated by PDGFR
US9181188B2 (en) 2002-02-11 2015-11-10 Bayer Healthcare Llc Aryl ureas as kinase inhibitors
US9856234B2 (en) 2006-10-21 2018-01-02 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
US10100048B2 (en) 2010-09-27 2018-10-16 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US11958846B2 (en) 2018-08-17 2024-04-16 Novartis Ag Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01009077A (es) * 1999-03-12 2002-03-27 Boehringer Ingelheim Pharma Composiciones heterociclicos aromaticos como agentes anti-inflamatorios.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014681A1 (fr) * 1995-10-16 1997-04-24 Fujisawa Pharmaceutical Co., Ltd. Composes heterocycliques tels que des h+-atpases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014681A1 (fr) * 1995-10-16 1997-04-24 Fujisawa Pharmaceutical Co., Ltd. Composes heterocycliques tels que des h+-atpases

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262082B1 (en) 1998-12-09 2001-07-17 BLOOM Jonathan Diaminopyridine-containing thiourea inhibitors of herpes viruses
US6271236B1 (en) 1998-12-09 2001-08-07 BLOOM Jonathan Diaminopyridine-containing thiourea inhibitors of herpes virus
US6555561B2 (en) 1998-12-09 2003-04-29 Wyeth Diaminopyridine-containing thiourea inhibitors of herpes viruses
WO2000034269A1 (fr) * 1998-12-09 2000-06-15 American Home Products Corporation Inhibiteurs de thio-uree des virus de l'herpes
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7897623B2 (en) 1999-01-13 2011-03-01 Bayer Healthcare Llc ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
US8841330B2 (en) 1999-01-13 2014-09-23 Bayer Healthcare Llc Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7381744B1 (en) * 1999-03-05 2008-06-03 The United States Of America As Represented By The Department Of Health And Human Services Method of treating osteoporosis comprising vacuolar-type (H+)-ATPase-inhibiting compounds
WO2001017562A1 (fr) * 1999-09-02 2001-03-15 Yamanouchi Pharmaceutical Co., Ltd. Agents promoteurs de l'osteogenese
US7241758B2 (en) 1999-11-16 2007-07-10 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
EP1232150B1 (fr) * 1999-11-16 2007-10-10 Boehringer Ingelheim Pharmaceuticals Inc. Derives d'uree utilises comme agents anti-inflammatoires
US6815451B2 (en) 2001-03-27 2004-11-09 Actelion Pharmaceuticals Ltd. 1,2,3,4-Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists
WO2002085857A2 (fr) * 2001-04-20 2002-10-31 Bayer Corporation Inhibition de la kinase raf a l'aide d'urees de quinolyl, d'isoquinolyl ou de pyridyl
WO2002085857A3 (fr) * 2001-04-20 2003-01-16 Bayer Ag Inhibition de la kinase raf a l'aide d'urees de quinolyl, d'isoquinolyl ou de pyridyl
US7375227B2 (en) 2001-12-04 2008-05-20 Actelion Pharmaceuticals Ltd. Quinoline derivatives
US9181188B2 (en) 2002-02-11 2015-11-10 Bayer Healthcare Llc Aryl ureas as kinase inhibitors
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
US8618141B2 (en) 2002-02-11 2013-12-31 Bayer Healthcare Llc Aryl ureas with angiogenesis inhibiting activity
US8242147B2 (en) 2002-02-11 2012-08-14 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
WO2004026836A2 (fr) * 2002-09-17 2004-04-01 Actelion Pharmaceuticals Ltd Derives de 1-pyridin-4-yl-uree
WO2004026836A3 (fr) * 2002-09-17 2005-01-20 Actelion Pharmaceuticals Ltd Derives de 1-pyridin-4-yl-uree
US8796250B2 (en) 2003-05-20 2014-08-05 Bayer Healthcare Llc Diaryl ureas for diseases mediated by PDGFR
US8637553B2 (en) 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US7750161B2 (en) 2003-09-26 2010-07-06 Daniel Bur Pyridine derivatives
US8067601B2 (en) 2004-10-12 2011-11-29 Actelion Pharmaceticals Ltd. 1-[2-(4-benzyl-4-hydroxy-piperidin-1 -yl )-ethyl]-3-(2-methyl-quinolin- 4-yl)- urea as crystalline sulfate salt
US9856234B2 (en) 2006-10-21 2018-01-02 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
US10100048B2 (en) 2010-09-27 2018-10-16 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US20120172376A1 (en) * 2010-12-30 2012-07-05 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) * 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9540370B2 (en) 2010-12-30 2017-01-10 Abbvie Deutschland Gmbh & Co., Kg. Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US11958846B2 (en) 2018-08-17 2024-04-16 Novartis Ag Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors

Also Published As

Publication number Publication date
CA2342804C (fr) 2007-11-13
AUPP003197A0 (en) 1997-11-20
JP2002510334A (ja) 2002-04-02
CA2342804A1 (fr) 1999-03-11

Similar Documents

Publication Publication Date Title
WO1999021835A1 (fr) DERIVES DE QUINOLINE UTILISES COMME INHIBITEURS DE H+ATPase ET COMME INHIBITEURS DE RESORPTION OSSEUSE
EP0876345B1 (fr) Composes heterocycliques tels que des h+-atpases
EP0596406B1 (fr) Imidazo (1,2-a) pyridines antagonistes de la bradykinine
ES2737696T3 (es) Pirazolopiridinas y pirazolopirimidinas
AU705883B2 (en) Pyridopyrimidones, quinolines and fused N-heretocycles as bradykinin antagonists
US6541480B2 (en) 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor
EP0373891B1 (fr) Agents antitumoraux
EP0224919B1 (fr) Composés de thiazol, leur procédé de préparation et composition pharmaceutique les contenant
US7547779B2 (en) Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors
WO1997010219A1 (fr) Derives benzimidazoliques, et leur utilisation dans la prevention et le traitement de maladies osseuses
US7842701B2 (en) Pyrazoloquinolone derivative and use thereof
CA2954814A1 (fr) Composes d'isonicotinamide et utilisation comme inhibiteurs de kallicreines de plasma
SK1942001A3 (en) 1h-imidazopyridine derivatives
SK3542002A3 (en) Pteridinones as kinase inhibitors
JP2007516212A (ja) 自己免疫疾患の処置における使用のための２−アミノピリミジンおよび２−アミノピリジン−４−カルバメート
US5750699A (en) Method of preparing certain 3-halo-imidazopyridines
US6288061B1 (en) Imidazole derivatives
JPS6110584A (ja) イミダゾイソキノリン化合物およびその製造方法
EP0842933A1 (fr) Nouveaux derives de naphtyridine
JPH10291988A (ja) 複素環式化合物
WO1994003439A1 (fr) Composes tricycliques a activite antiproliferatrice
JPH0948780A (ja) 新規ナフチリジン誘導体
OA11554A (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA CN JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA